These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 15626738

  • 1. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
    Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2005 May 01; 105(9):3679-85. PubMed ID: 15626738
    [Abstract] [Full Text] [Related]

  • 2. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2004 Mar 15; 103(6):2266-75. PubMed ID: 14604974
    [Abstract] [Full Text] [Related]

  • 3. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.
    Blood; 2003 Feb 15; 101(4):1494-504. PubMed ID: 12406902
    [Abstract] [Full Text] [Related]

  • 4. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.
    Blood; 2005 Jul 01; 106(1):265-73. PubMed ID: 15769897
    [Abstract] [Full Text] [Related]

  • 5. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.
    Blood; 2003 Jul 15; 102(2):646-51. PubMed ID: 12663439
    [Abstract] [Full Text] [Related]

  • 6. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R, Miething C, Thiede C, Peschel C, Duyster J.
    Blood; 2005 Jun 15; 105(12):4792-9. PubMed ID: 15718420
    [Abstract] [Full Text] [Related]

  • 7. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.
    Blood; 2000 Dec 01; 96(12):3907-14. PubMed ID: 11090077
    [Abstract] [Full Text] [Related]

  • 8. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.
    J Biol Chem; 2003 Aug 29; 278(35):32892-8. PubMed ID: 12815052
    [Abstract] [Full Text] [Related]

  • 9. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 29; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 10. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 11. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
    Levis M, Tse KF, Smith BD, Garrett E, Small D.
    Blood; 2001 Aug 01; 98(3):885-7. PubMed ID: 11468194
    [Abstract] [Full Text] [Related]

  • 12. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep 01; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 13. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan 01; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 14. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, Stone R.
    Cancer Res; 2005 Aug 15; 65(16):7338-47. PubMed ID: 16103085
    [Abstract] [Full Text] [Related]

  • 15. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Wang LY, Chang WH.
    Leukemia; 2003 May 15; 17(5):883-6. PubMed ID: 12750701
    [Abstract] [Full Text] [Related]

  • 16. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 15; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 17. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
    Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D.
    Blood; 2002 Jun 01; 99(11):3885-91. PubMed ID: 12010785
    [Abstract] [Full Text] [Related]

  • 18. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
    Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer FD, Hochhaus A, Fischer T, Scholl S.
    Br J Haematol; 2012 May 01; 157(4):483-92. PubMed ID: 22409268
    [Abstract] [Full Text] [Related]

  • 19. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A, Heidel F, Fischer T, Rönnstrand L.
    Ann Hematol; 2018 May 01; 97(5):773-780. PubMed ID: 29372308
    [Abstract] [Full Text] [Related]

  • 20. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.
    Blood; 2012 Apr 26; 119(17):4026-33. PubMed ID: 22411868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.